

NEUROCRINE BIOSCIENCES INC

Form 8-K

September 05, 2006

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of the earliest event reported): September 5, 2006**

**NEUROCRINE BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other  
jurisdiction of  
incorporation or  
organization)

**0-22705**

(Commission File  
Number)

**33-0525145**

(IRS Employer Identification  
No.)

**12790 El Camino Real**

(Address of principal executive offices)

**92130**

(Zip Code)

Registrant's telephone number, including area code: **(858) 617-7600**

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01 Other Events**

On September 5, 2006, Neurocrine Biosciences, Inc. issued a press release to provide an update on the Company's meeting with the Food and Drug Administration (FDA) related to the indiplon capsules New Drug Application end-of-review meeting.

**Item 9.01 Financial Statements and Exhibits**

99.1 Press Release dated September 5, 2006

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: September 5, 2006

NEUROCRINE BIOSCIENCES, INC.

/s/ MARGARET E. VALEUR-JENSEN  
Margaret E. Valeur-Jensen  
Executive Vice President, General Counsel  
and Corporate Secretary